Ad5-nCoV is the first novel coronavirus vaccine for COVID-19 in a Phase 1 Clinical Trial in China. The vaccine candidate is built upon CanSinoBIO’s adenovirus-based viral vector vaccine technology platform.
The Ad5-nCoV vaccine candidate is a genetically engineered vaccine candidate with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein.
Results from preclinical animal studies of Ad5-nCoV show that the vaccine candidate can induce a strong immune response in animal models. Preclinical animal safety studies also demonstrated a good safety profile.